Mazdutide

Mazdutide: A Dual Receptor Agonist for Weight Loss and Blood Glucose Control

What Is Mazdutide?

Mazdutide is a novel medication designed for the treatment of obesity and type 2 diabetes. It received approval for use in China in June 2025 and is administered via injection once weekly.

How Does Mazdutide Work?

Mazdutide operates as a dual receptor agonist, targeting two specific receptors: GLP-1R (glucagon-like peptide 1 receptors) and glucagon receptors. This unique mechanism is what sets Mazdutide apart.

• GLP-1 Role:
  • Produced in response to meals, it influences:
    • Eating behavior
    • Metabolism
    • Insulin secretion
• Glucagon Role:
  • Secreted during low blood glucose levels, fasting, or exercise, it alters metabolism and energy expenditure.

Mechanism of Action

Mazdutide achieves its effects by:

• Activating GLP-1 receptors to stimulate insulin secretion when glucose levels are high.
• Activating glucagon receptors to simulate a fasted state, promoting glucose release from the liver and increasing energy expenditure.

Benefits of Mazdutide

By binding to both GLP-1 and glucagon receptors, Mazdutide provides several benefits:

1. Reduced Appetite and Increased Satiety:
   • Promotes feelings of fullness and delays gastric emptying, leading to reduced calorie intake.
2. Improved Blood Glucose Control:
   • Prevents spikes in blood glucose levels post-meal and reduces the risk of hypoglycemia.
3. Increased Energy Expenditure and Weight Loss:
   • Stimulates thermogenesis and lipid oxidation, contributing to weight loss.

Side Effects

Common side effects associated with Mazdutide are primarily gastrointestinal, including:

• Nausea
• Vomiting
• Diarrhea
• Bloating
• Decreased appetite

While hypoglycemia is possible, it is not common. These side effects can be managed by gradually increasing the dosage during the initial weeks of treatment.

Comparison with Other Similar Drugs

• Efficacy:
  • Mazdutide has shown up to a 15% reduction in body weight over 24 weeks, with an average weight loss of 13.3%.
  • In phase 3 trials, participants lost an average of 11% to 14.01% depending on the dosage after 48 weeks.
• Semaglutide:
  • Stimulates only GLP-1 receptors, achieving a mean weight loss of up to 14.9% over 68 weeks.
• Tirzepatide:
  • Another dual receptor agonist that activates GIP receptors instead of glucagon receptors. It has shown a 5-7% weight reduction over a similar duration.

Why Buy From Us?

• Tamper-Proof Packaging: Ensures product integrity.
• Experienced Customer Support: Assistance from knowledgeable staff.
• Fast and Discreet Shipping: Global delivery options available.
• Competitive Bulk Pricing: Discounts for institutions and laboratories.

Conclusion

Mazdutide represents a promising new option for weight loss and type 2 diabetes management, offering significant results in a shorter time frame compared to similar medications. With its dual receptor activation and favorable side effect profile, it is likely to see increased usage in clinical settings as it becomes more widely available.

References

1. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-
   130. doi:10.1016/j.molmet.2019.09.010
2. Winther JB, Holst JJ. Glucagon agonism in the treatment of metabolic diseases including type
   2 diabetes mellitus and obesity. Diabetes Obes Metab. 2024;26(9):3501-3512.
   doi:10.1111/dom.15693
3. JIANG H, JI L, ZHANG Y, et al. 1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults
   with BMI of 30 kg/m2 or more. Diabetes. 2024;73(Supplement_1):1866-LB.
   doi:10.2337/db24-1866-LB
4. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese
   overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289.
   doi:10.1038/s41467-023-44067-4
5. Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With
   Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes
   Care. 2024;47(1):160-168. doi:10.2337/dc23-1287
6. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
   N Engl J Med. 2025;392(22):2215-2225. doi:10.1056/NEJMoa2411528
7. Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist
   mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A
   randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
   eClinicalMedicine. 2022;54:101691. doi:10.1016/j.eclinm.2022.101691
8. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with
   Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
9. Trinh H, Donovan A, McAdam-Marx C. Real-world effectiveness of tirzepatide versus
   semaglutide for weight loss in overweight or obese patients in an ambulatory care setting.
   Diabetes Obes Metab. 2025;27(6):3523-3525. doi:10.1111/dom.16343